Jeff Yass’s Tonix Pharmaceuticals TNXP Stock Holding History

Jeff Yass’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$549K	Buy	43,034 +13,455	+45%	+$174K	﹤0.01%	9695
2026 Q1	$407K	Sell	29,579 -83	-0.3%	-$1.28K	﹤0.01%	10166
2025 Q4	$463K	Buy	29,662 +20,912	+239%	+$386K	﹤0.01%	8974
2025 Q3	$211K	Sell	8,750 -258	-3%	-$9.57K	﹤0.01%	10878
2025 Q2	$324K	Buy	+9,008	New	+$236K	﹤0.01%	10164
2022 Q2	–	Hold	0	–	-$6K	–	13949
2022 Q1	–	Hold	0	–	–	–	12804
2021 Q4	–	Hold	0	–	–	–	12605
2021 Q2	–	Sell	-1	Closed	-$1.01M	–	13265
2021 Q1	$1.01M	Buy	+1	New	+$765K	﹤0.01%	7713
2020 Q3	–	Hold	0	–	-$13K	–	11150
2020 Q2	–	Hold	0	–	–	–	9960
2020 Q1	–	Hold	0	–	–	–	10078
2019 Q4	–	Hold	0	–	-$11K	–	10647
2019 Q3	–	Hold	0	–	–	–	10011
2019 Q2	–	Hold	0	–	–	–	10041
2018 Q3	–	Hold	0	–	-$220K	–	10244
2018 Q2	–	Hold	0	–	–	–	8445
2017 Q4	–	Hold	0	–	-$207K	–	9906
2017 Q3	–	Hold	0	–	–	–	7966
2017 Q2	–	Hold	0	–	–	–	7113
2017 Q1	–	Hold	0	–	–	–	5635
2016 Q4	–	Hold	0	–	–	–	9486
2016 Q3	–	Hold	0	–	–	–	8260
2015 Q4	–	Hold	0	–	–	–	9983
2015 Q3	–	Hold	0	–	–	–	8909
2014 Q4	–	Hold	0	–	-$147K	–	10102
2014 Q3	–	Hold	0	–	–	–	8905

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's TNXP Position: Q2 2026 in Review

Jeff Yass increased its Tonix Pharmaceuticals (TNXP) stake by 45% in Q2 2026, buying an estimated $174K and bringing the position to 43,034 shares worth $549K. The position accounts for ﹤0.01% of the portfolio, ranked #9695.

Jeff Yass first reported a position in TNXP in Q1 2021 and has held it in 6 quarters since. The position peaked at $1.01M in Q1 2021. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Jeff Yass held 43,034 shares of Tonix Pharmaceuticals worth $549K as of Q2 2026.
Jeff Yass bought 13,455 Tonix Pharmaceuticals shares in Q2 2026, an estimated $174K.
Tonix Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9695 holding.
Jeff Yass first reported a position in Tonix Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
Jeff Yass's Tonix Pharmaceuticals position peaked at $1.01M in Q1 2021.
102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.